Full Text Full Text (PDF) Correction (v163,p1648) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Valenstein, M. Articles by Blow, F. C. Search for Related Content PubMed Citation Articles by Valenstein, M. Articles by Blow, F. C. Minority Issues Other Addictive Disorders Anxiety Disorders (General) Depression Posttraumatic Stress Disorder Other Patient Groups/Issues Suicide Anticonvulsants Antidepressants Lithium Other Somatic Therapy Atypical Neuroleptics

What Happened to Lithium? Antidepressant Augmentation in Clinical Settings

OBJECTIVE: Antidepressant augmentation is recommended when patients do not respond to antidepressant monotherapy. However, little is know about antidepressant augmentation in clinical settings and whether these practices reflect the research evidence. METHOD: The authors identified 244,859 patients in Veterans Administration mental health settings with a diagnosis of depression and an antidepressant prescription during fiscal year 2002. Patients with schizophrenia, dementia, or bipolar I disorder were excluded. The authors examined the prevalence and characteristics of antidepressant augmentation during the year, defined as receiving an antidepressant and an augmenting agent (lithium, second-generation antipsychotics, combinations of antidepressants, anticonvulsants, or "other") for 60 consecutive days in specified doses for those without other clinical indications. Mixed-effect models were used to examine predictors of augmentation. RESULTS: Some patients (22%) received an augmenting agent. The most commonly used agents were a second antidepressant (11%) and a second-generation antipsychotic (7%). Only 0.5% of the patients received lithium. Whites, younger patients, and those with a prior hospitalization were more likely to receive augmentation. African Americans were more likely to receive antipsychotic augmentation; whites were more likely to receive lithium. CONCLUSIONS: Antidepressant augmentation is common in clinical settings. Although lithium currently has the most research support, antipsychotic medications and a second antidepressant are the most widely used augmenting agents. Many augmenting agents are used across clinical and demographic groups. Research is needed on the relative effectiveness of these agents, along with efforts to promote the use of agents with the greatest level of research support.

This article has been cited by other articles:

				J.-M. Beaulieu, X. Zhang, R. M. Rodriguiz, T. D. Sotnikova, M. J. Cools, W. C. Wetsel, R. R. Gainetdinov, and M. G. Caron Role of GSK3{beta} in behavioral abnormalities induced by serotonin deficiency PNAS, January 29, 2008; 105(4): 1333 - 1338. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2006 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us